Stuart C Gordon1, Lois E Lamerato2, Loralee B Rupp3, Scott D Holmberg4, Anne C Moorman4, Philip R Spradling4, Eyasu Teshale4, Fujie Xu4, Joseph A Boscarino5, Vinutha Vijayadeva6, Mark A Schmidt7, Nancy Oja-Tebbe2, Mei Lu2. 1. Division of Gastroenterology and Hepatology, Henry Ford Health System, Detroit, Michigan, USA. 2. Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA. 3. Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA. 4. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 5. Center for Health Research, Geisinger Health System, Danville, Pennsylvania, USA. 6. Center for Health Research, Kaiser Permanente-Hawaii, Honolulu, Hawaii, USA. 7. Center For Health Research, Kaiser Permanente-Northwest, Portland, Oregon, USA.
Abstract
OBJECTIVES: The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker. METHODS: Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during 2006-2010 were included. Cirrhosis was identified through liver biopsy reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores ≥5.88. Demographic and clinical characteristics associated with cirrhosis were identified through multivariable logistic modeling. RESULTS: Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 (54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently associated with higher odds of cirrhosis (all, P<0.05). Conversely, private health insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis. CONCLUSIONS: A high proportion of patients with biopsy-confirmed cirrhosis are not assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed.
OBJECTIVES: The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker. METHODS:Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during 2006-2010 were included. Cirrhosis was identified through liver biopsy reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores ≥5.88. Demographic and clinical characteristics associated with cirrhosis were identified through multivariable logistic modeling. RESULTS: Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 (54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently associated with higher odds of cirrhosis (all, P<0.05). Conversely, private health insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis. CONCLUSIONS: A high proportion of patients with biopsy-confirmed cirrhosis are not assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest that cirrhosis in CHCpatients may be significantly underdocumented and underdiagnosed.
Authors: M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess Journal: N Engl J Med Date: 1999-09-16 Impact factor: 91.245
Authors: Stuart C Gordon; Paul J Pockros; Norah A Terrault; Robert S Hoop; Ami Buikema; David Nerenz; Fayez M Hamzeh Journal: Hepatology Date: 2012-10-09 Impact factor: 17.425
Authors: Stephen E Livingston; Heike Deubner; Dana L Bruden; Brian J McMahon; Chriss E Homan; Lisa J Townshend-Bulson; Michael G Bruce; Thomas W Hennessy; James L Williams; David R Gretch Journal: Can J Gastroenterol Date: 2010-07 Impact factor: 3.522
Authors: Carrie McAdam-Marx; Lisa J McGarry; Christopher A Hane; Joseph Biskupiak; Baris Deniz; Diana I Brixner Journal: J Manag Care Pharm Date: 2011-09
Authors: Reena Mahajan; Jian Xing; Stephen J Liu; Kathleen N Ly; Anne C Moorman; Loralee Rupp; Fujie Xu; Scott D Holmberg Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: J Li; S C Gordon; L B Rupp; T Zhang; J A Boscarino; V Vijayadeva; M A Schmidt; M Lu Journal: J Viral Hepat Date: 2014-01-29 Impact factor: 3.728
Authors: Mei Lu; Jia Li; Loralee B Rupp; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Sheri Trudeau; Stuart C Gordon Journal: Liver Int Date: 2017-07-21 Impact factor: 5.828
Authors: Marija Zeremski; Rositsa B Dimova; Jaroslaw Pillardy; Ype P de Jong; Ira M Jacobson; Andrew H Talal Journal: J Infect Dis Date: 2016-08-02 Impact factor: 5.226
Authors: Winston E Abara; P Spradling; Y Zhong; A Moorman; E H Teshale; L Rupp; S C Gordon; M Schmidt; J A Boscarino; Y G Daida; S D Holmberg Journal: J Gastrointest Cancer Date: 2020-06
Authors: Hussien Ahmed; Abdelrahman Ibrahim Abushouk; Amr Menshawy; Arwa Mohamed; Ahmed Negida; Samah A Loutfy; Mohamed M Abdel-Daim Journal: Clin Drug Investig Date: 2017-11 Impact factor: 2.859
Authors: Brigg Reilley; Jessica Leston; Mona Doshani; Dana L Haberling; Marissa Person; Thomas Weiser; Melissa Collier; Jonathan Iralu; Jorge Mera; Rick Haverkate Journal: J Community Health Date: 2018-12
Authors: H Nina Kim; Robin M Nance; Vincent Lo Re; Michael J Silverberg; Ricardo Franco; Timothy R Sterling; Edward R Cachay; Michael A Horberg; Keri N Althoff; Amy C Justice; Richard D Moore; Marina Klein; Heidi M Crane; Joseph A Delaney; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771
Authors: Anne C Moorman; Loralee B Rupp; Stuart C Gordon; Yuna Zhong; Jian Xing; Mei Lu; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Eyasu H Teshale; Philip R Spradling; Scott D Holmberg Journal: Infect Dis Clin North Am Date: 2018-06 Impact factor: 5.982
Authors: Divya Ramnath; Katharine M Irvine; Samuel W Lukowski; Leigh U Horsfall; Zhixuan Loh; Andrew D Clouston; Preya J Patel; Kevin J Fagan; Abishek Iyer; Guy Lampe; Jennifer L Stow; Kate Schroder; David P Fairlie; Joseph E Powell; Elizabeth E Powell; Matthew J Sweet Journal: JCI Insight Date: 2018-07-26
Authors: Sameed Ahmed M Khatana; Thomas C Hanff; Ashwin S Nathan; Elias J Dayoub; E Wilson Grandin; J Eduardo Rame; Alexander C Fanaroff; Jay Giri; Peter W Groeneveld Journal: Circ Heart Fail Date: 2021-05-15 Impact factor: 8.790